A Phase 1, Randomized, Double-blind, Placebo- controlled, Multiple Ascending Dose Study of DT-216 in Adult Patients with Friedreich Ataxia: Initial Study Results August 2023 1 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited ...